General Information of Drug (ID: DME9NYV)

Drug Name
BI 905711 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DME9NYV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting TRAIL receptor 2 (TRAIL-R2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Conatumumab DM2UOSN Colorectal cancer 2B91.Z Phase 2 [3]
Lexatumumab DMOS5JZ Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
Anti-DR5 cells DMYKZB3 Hepatocellular carcinoma 2C12.02 Phase 1/2 [5]
IGM-8444 DMFJXDZ Hematologic tumour 2B33.Y Phase 1 [6]
INBRX-109 DMUNSPI Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
DS-8273 DMJPUDW Colorectal cancer 2B91.Z Phase 1 [8]
GEN1029 DMV8IWJ Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
RhApo2L/TRAIL DMIAZJ9 Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1/2 [3]
LBY-135 DMSRD5U Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [10]
HGS-TR2J DM0W2TA Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TRAIL receptor 2 (TRAIL-R2) TTW20TU TR10B_HUMAN Activator [2]

References

1 ClinicalTrials.gov (NCT04137289) A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer. U.S. National Institutes of Health.
2 Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist. Mol Cancer Ther. 2021 Jan;20(1):96-108.
3 Clinical pipeline report, company report or official report of Amgen (2009).
4 National Cancer Institute Drug Dictionary (drug id 528015).
5 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
6 Clinical pipeline report, company report or official report of IGM Biosciences.
7 Clinical pipeline report, company report or official report of Inhibrx.
8 First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):298-306.
9 National Cancer Institute Drug Dictionary (drug name Tilogotamab).
10 Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs. 2014 Feb;32(1):135-44.
11 Enhancement of Glioma Radiation Therapy and Chemotherapy Response with Targeted Antibody Therapy Against Death Receptor 5. Int J Radiat Oncol Biol Phys. 2008 June 1; 71(2): 507-516.